Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrazole SCHEMBL735500 | 0.99 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL6037735 | 0.99 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL225087 | 0.99 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL5145009 | 0.89 | HTR2A (0.31) | HTR2AHTR1AHTR2CHTR2B | |
| O-Tolylamine SCHEMBL7116171 | 0.89 | HTR2A (0.32) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL23488 | 0.87 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL29356973 | 0.87 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| Phosphoric Acid SCHEMBL8156858 | 0.85 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL20492883 | 0.85 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL5058499 | 0.85 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317840-A1 | AUTOMATED DETERMINATION OF CHLAMYDIA INFECTION-FORMING UNITS | MERCK SHARP & DOHME CORP. | 2009-12-24 | — | — | US | claimed |
| WO-2008013772-A2 | AUTOMATED DETERMINATION OF CHLAMYDIA INFECTION-FORMING UNITS | MERCK & CO., INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-4239336-B1 | METHOD OF MANUFACTURING A MICROTITRATION PLATE WITH CAPTURE MOLECULAR COATINGS AND MICROTITRATION PLATE | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2024-01-10 | — | — | EP | disclosed |
| EP-3502686-B1 | ANTIGEN DETECTION OF TRICHINELLA | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-4239336-A1 | METHOD OF MANUFACTURING A MICROTITRATION PLATE WITH CAPTURE MOLECULAR COATINGS AND MICROTITRATION PLATE | Euroimmun Medizinische Labordiagnostika AG (DE) | 2023-09-06 | — | — | EP | disclosed |
| CN-113939583-A | Biomarkers and targets for diagnosis, assessment of prognosis and treatment of ankylosing spondylitis | 台湾地区“中央研究院” | 2022-01-14 | — | — | CN | disclosed |
| US-20210301318-A1 | A BIOMARKER AND TARGET FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF ANKYLOSING SPONDYLITIS | ACADEMIA SINICA (TW) | 2021-09-30 | — | — | US | disclosed |
| EP-3821002-A1 | A BIOMARKER AND TARGET FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF ANKYLOSING SPONDYLITIS | Academia Sinica (TW) | 2021-05-19 | — | — | EP | disclosed |
| US-20210009959-A1 | METHODS FOR ENHANCING OSTEOGENIC DIFFERENTIATION USING VITAMIN D | AMOABEDINY GHASSEM (IR) | 2021-01-14 | — | — | US | disclosed |
| EP-3009507-B1 | SIGNAL FOR PACKAGING OF INFLUENZA VIRUS VECTORS | WISCONSIN ALUMNI RES FOUND (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200115456-A1 | ANTIBODY, KIT COMPRISING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2020-04-16 | — | — | US | disclosed |
| WO-1998028438-A1 | PROCESS FOR DETECTING POINT MUTATIONS IN WHICH THE PRIMER IS BOUND TO A SOLID SUPPORT AND EXTENSION DOES NOT OCCUR IF THE TERMINAL NUCLEOTIDE(S) MIS-MATCH | DIATECH PTY. LTD. (AU) | 1998-07-02 | — | — | WO | disclosed |
| WO-1997046706-A1 | METHODS FOR DETECTION OF REARRANGED DNA | UNIVERSITY OF ALBERTA (CA) | 1997-12-11 | — | — | WO | disclosed |
| US-5532133-A | IMMUNOLOGY | NEW YORK UNIVERSITY (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0467078-B1 | An analyte-subtitute reagent for use in specific binding assay methods, devices and kits | ABBOTT LAB (US) | 1996-05-08 | — | — | EP | disclosed |
| US-5501985-A | DETERMINATION OF LOW MOLECULAR WEIGHT, STEROIDS, HORMONES, ANTIBIOTICS, DRUGS | ABBOTT LABORATORIES (US) | 1996-03-26 | — | — | US | disclosed |
| US-5340748-A | Analyte-substitute reagent for use in specific binding assay methods, devices and kits | ABBOTT LABORATORIES (US) | 1994-08-23 | — | — | US | disclosed |
| US-5200508-A | Cell surface antigen that binds with L6 monoclonal antibody | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON HEALTH SCIENCES UNIVERSITY (US) | 1993-04-06 | — | — | US | disclosed |
| EP-0467078-A2 | An analyte-subtitute reagent for use in specific binding assay methods, devices and kits | ABBOTT LABORATORIES (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0399257-A1 | Cell surface antigen that binds with L6 Monoclonal antibody | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210301318-A1 | A BIOMARKER AND TARGET FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF ANKYLOSING SPONDYLITIS | SOST, TNF, CD44 | HTR2A 3909/4885HTR1A 3549/4885HTR2C 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.